OncLive SOSS

Authors

Nabil F. Saba, MD, FACP

Latest:

Dr Saba on Findings from the CONTINUUM Trial of Sintilimab in Nasopharyngeal Cancer

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Nabil F Saba, MD, FACP, Emory University

Latest:

Managing Adverse Events With Tipifarnib

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.

Nabil P. Rizk, MD, MS, MPH

Latest:

Dr. Rizk on the Evolution of Surgery in Lung Cancer

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Nadine Abi-Jaoudeh, MD

Latest:

Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

Nadine J. Barrett, PhD

Latest:

Dr. Barrett on Addressing Cancer Disparities

Nadine J. Barrett, PhD, Duke Cancer Institute, discusses the need to address cancer disparities during the Association of Community Cancer Centers (ACCC) 43rd Annual Meeting.

Nadine M. Tung, MD

Latest:

Dr. Tung Discusses the Role of Olaparib in Breast Cancer

Nadine M. Tung, MD, associate professor of medicine, Harvard Medical School, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Center, discusses the role of olaparib (Lynparza) in the treatment of patients with breast cancer.

Nadine M. Tung, MD, Harvard Medical School

Nadir Arber, MD, MHA

Latest:

Dr. Arber on Aspirin for Colorectal Cancer Prevention

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Nagashree Seetharamu, MD

Latest:

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Nagi B. Kumar, PhD

Latest:

Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Nagy Elsayyad, MD

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Nagy M. Elsayad

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Naifa Busaidy, MD, FACP, FACE, University of Texas MD Anderson Cancer Center

Naifa L. Busaidy, MD, FACP, FACE

Latest:

Novel Treatment Advances in Differentiated Thyroid Cancer

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Naifa L. Busaidy, MD, MD Anderson

Naiyer A, Rizvi,MD

Latest:

Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

Naiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.

Naiyer A. Rizvi, MD, Columbia University Medical Center

Naiyer A. Rizvi, MD, NewYork-Presbyterian Hospital

Naiyer Rizvi, MD, Columbia

Naiyer Rizvi, MD, Columbia University Medical Center